Award
BPA #36E79727A0005
VA Pharmaceutical BPA for Rare-Disease Treatments
Buyer
Department of Veterans Affairs
Award Amount
$33,094,350.00
Ceiling
$33,094,350.00
Awarded
October 28, 2026
Period of Performance
Oct 28, 2026 – Oct 27, 2027
Identifier
36E79727A0005
NAICS
325412
This is a blanket purchase agreement (BPA) under the Department of Veterans Affairs’ Federal Supply Schedule contract. It enables the VA to order carglumic acid, Cystadane, Signifor, Isturisa, and Cystadrops—prescription medicines used to treat rare or specialized conditions. The supplier, Recordati Rare Diseases, Inc., specializes in pharmaceuticals for rare diseases and related conditions. The agreement supports access to these treatments for veteran healthcare and provides a purchasing arrangement for anticipated needs; the record does not identify specific order quantities or delivery locations. The BPA is associated with the parent FSS contract, which was awarded through full and open competition. Competition details for this BPA itself are not provided. The BPA is scheduled to run from late 2026 through late 2027, with potential performance shown as extending beyond that period. No acquisition program, subcontractors, prior related contracts beyond the parent FSS contract, or original solicitation details are provided.
Description
BPA FOR CARGLUMIC ACID, CYSTADANE, SIGNIFOR, ISTURSIA, AND CYSTADROPS